[
    {
        "utterance": "Tom Mansell: Sensing and regulation is a big part of the plan here. But for now, we're in the very preliminary stages of that. ",
        "annotations": {
            "explain or define term or concept": "Tom clarifies that while sensing and regulation are important, the project is currently in its early stages.",
            "provide supporting evidence": "Tom supports his statement about the project's status by mentioning they are in the 'very preliminary stages'."
        }
    },
    {
        "utterance": "Tanya Nguyen: To follow up on what you're saying and also what Jay had mentioned earlier, and I have no idea how to do this, but it would be so cool to develop a way to kind of individually determine what someone's microbiome is at homeostasis, their ideal kind of microbiome environment, whether that be composition, metabolites, chemicals, and then use that as a baseline, and then being able to develop, you know, these different chemically engineered bacteria then produce specific metabolites to keep that person at that specific ideal level or attain an ideal level for them to then minimize their clinical symptoms or functioning. I think that would be a really cool idea, no idea how to get there, but happy to talk about it further and develop that. ",
        "annotations": {
            "present new idea": "Tanya presents a novel idea of individually determining a person's ideal microbiome environment and using engineered bacteria to maintain it, minimizing clinical symptoms.",
            "expand on existing idea": "Tanya builds upon the previous discussion of sensing and regulation in the microbiome by suggesting a specific method for personalized intervention.",
            "express enthusiasm": "Tanya expresses excitement about the potential of her idea by describing it as \"cool\" and emphasizing its potential benefits."
        }
    },
    {
        "utterance": "Tom Mansell: I think you could do it with one molecule. I don't know about all of those. But you know, if it's short chain fatty acids, I think that that's a great idea. ",
        "annotations": {
            "expand on existing idea": "Tom expands on Tanya's idea of personalized microbiome management by suggesting focusing on a single molecule like short-chain fatty acids.",
            "reject idea": "Tom expresses doubt about managing the entire microbiome but suggests a more feasible approach.",
            "express agreement": "Tom agrees that focusing on short-chain fatty acids is a good idea, supporting Tanya's overall concept."
        }
    },
    {
        "utterance": "Tom Mansell: Right now, I think, in general, the approaches, well, let's just make more, make more given prebiotics, given probiotics that we think are going to make butyrate. But you know, there might, there's probably a level that's too high, right? ",
        "annotations": {
            "expand on existing idea": "Tom expands on the previously mentioned idea of using prebiotics and probiotics by suggesting increasing production and considering potential upper limits.",
            "provide supporting evidence": "Tom supports his idea by mentioning the goal of producing butyrate and acknowledging the possibility of excessive levels.",
            "propose decision": "Tom proposes the decision to increase the production of prebiotics and probiotics to make more butyrate."
        }
    },
    {
        "utterance": "Tom Mansell: Do they take 12 different probiotic supplements every day to maintain that? You know, that's kind of the, yeah, so. ",
        "annotations": {
            "ask clarifying question": "Tom is asking a clarifying question about the practicality and feasibility of maintaining a specific microbiome balance through excessive supplement intake, questioning if individuals consume numerous probiotics daily to achieve this.",
            "express humor": "Tom uses humor to express skepticism about the practicality of taking 12 different probiotic supplements daily."
        }
    },
    {
        "utterance": "Tom Mansell: Yeah, no, that's a good idea. I mean, there is this whole, you know, what's a healthy microbiome, what's a healthy metabolome. That's, I think, going to vary by the host, and these host factors really influence these things, right? So, in addition to diet, of course, right? ",
        "annotations": {
            "acknowledge contribution": "Tom acknowledges Tanya's idea by saying \"that's a good idea.\"",
            "expand on existing idea": "Tom expands on Tanya's idea of personalized microbiome management by adding the concept of host factors influencing microbiome health.",
            "explain or define term or concept": "Tom explains the concept of healthy microbiome and metabolome and how it varies by host and diet."
        }
    },
    {
        "utterance": "Tom Mansell: You can blame it on behavior a little bit, but you can also, there's probably genetic factors too, right? That influence your microbiome. I'm just babbling, yeah. ",
        "annotations": {
            "expand on existing idea": "Tom expands on the idea of host factors influencing the microbiome by adding genetic factors to the previously mentioned behavioral factors.",
            "provide supporting evidence": "Tom supports the idea of host factors influencing microbiome by mentioning genetic factors.",
            "express humor": "Tom jokes that he is \"just babbling\" to downplay his contribution."
        }
    },
    {
        "utterance": "Jae Sung: I guess we have many more questions than answers. That's because that's how science works. Very interesting. ",
        "annotations": {
            "acknowledge contribution": "Jae Sung acknowledges the previous speakers' contributions to the discussion about the microbiome.",
            "explain or define term or concept": "Jae Sung explains that having more questions than answers is characteristic of how science progresses.",
            "express enthusiasm": "Jae Sung expresses interest in the topic by saying \"Very interesting.\""
        }
    },
    {
        "utterance": "Tom Mansell: I just have to say, as a chemical engineer, the thing that I have gotten most out of this discussion is this motility concept, right? And so we talked, you know, Emily framed the discussion as, this is a bioreactor, right? ",
        "annotations": {
            "acknowledge contribution": "Tom acknowledges Emily's contribution of framing the discussion by referring to her idea of the gut as a bioreactor.",
            "explain or define term or concept": "Tom explains what he has learned from the discussion, focusing on the concept of motility and the gut as a bioreactor."
        }
    },
    {
        "utterance": "Tom Mansell: This is, we have a whole core curriculum on this on reactor design. A key parameter of reactor design is residence time, which is the flow rate divided by the volume, right? So, that motility being the flow rate is going to influence the conversion or whatever fermentation products come out of your reactor, right? And so, I love this idea of influencing motility as a way to manipulate the microbiome and in doing so, manipulate the metabolome. ",
        "annotations": {
            "explain or define term or concept": "Tom defines \"residence time\" as a key parameter of reactor design, calculated as flow rate divided by volume, and explains how motility, as the flow rate, influences the microbiome and metabolome.",
            "expand on existing idea": "Tom expands on the bioreactor analogy and the concept of motility by connecting it to chemical engineering principles of reactor design and residence time.",
            "express enthusiasm": "Tom expresses his strong interest in the idea of influencing motility to manipulate the microbiome and metabolome."
        }
    },
    {
        "utterance": "Faranak Fattahi: It's circular, and then it affects motility again. ",
        "annotations": {
            "expand on existing idea": "This utterance builds upon the prior discussion of motility and reactor design by pointing out the circular relationship between motility and the microbiome.",
            "provide supporting evidence": "This utterance supports the idea of motility influencing the microbiome by highlighting the feedback loop where changes in the microbiome affect motility."
        }
    },
    {
        "utterance": "Tom Mansell: Right, yeah. Yes, of course. And you know, like many processes, it probably is a small disruption that becomes non-linear, and then, you know, that's when you end up in a disease state. I don't know, I'm not that kind of doctor, but ",
        "annotations": {
            "expand on existing idea": "Tom is building on the previous speaker's comment about circularity by adding the idea of a small disruption becoming non-linear and leading to a disease state.",
            "express humor": "Tom's self-deprecating comment about not being \"that kind of doctor\" is a form of humor."
        }
    },
    {
        "utterance": "Tom Mansell: So Faranak, I think we should talk about your ENS essay a little more. ",
        "annotations": {
            "assign task": "Tom assigns Faranak the task of discussing her ENS essay further.",
            "propose decision": "Tom proposes that he and Faranak discuss her ENS essay."
        }
    },
    {
        "utterance": "Faranak Fattahi: Absolutely, yeah, I'd love to. So we have actually done a lot of high throughput assays just looking at, you know, a library of neuroactive compounds. So these are around maybe 500 or 600 just small molecules that affect different neurotransmitter receptors. And turns out a lot of neurons in the GI tract respond to a variety of different neurotransmitter agonists and antagonists. And many of them could be influenced by microbial products. So basically, you have this constant effect from the microbiome on neuronal activity, which then affects the motility and other functions of the GI tract, so. ",
        "annotations": {
            "provide supporting evidence": "Faranak supports the idea of microbiome influencing motility by describing high throughput assays conducted on neuroactive compounds and their effect on neurotransmitter receptors in the GI tract.",
            "explain or define term or concept": "Faranak explains the concept of neuroactive compounds and their impact on neurotransmitter receptors, clarifying their role in GI tract functions and motility.",
            "expand on existing idea": "Faranak expands on the earlier discussion of motility and microbiome interaction by providing evidence of how microbial products can influence neuronal activity and thus, GI tract functions."
        }
    },
    {
        "utterance": "Jae Sung: Our slide definitely has the most text on it so far. ",
        "annotations": {
            "express humor": "Jae Sung makes a lighthearted joke about the amount of text on their presentation slide, likely comparing it to other presentations in the meeting."
        }
    },
    {
        "utterance": "Robin Michelle: I was wondering if you could elaborate a little bit more on these enteric organoids. We do just like the colonic and small intestine and also some pancreatic, but I didn't even know that you could do it with other, I guess, parts of the intestine. ",
        "annotations": {
            "ask clarifying question": "Robin Michelle asks for more details about enteric organoids, specifically if they can be made from other parts of the intestine, beyond the colonic, small intestine, and pancreas that she is familiar with."
        }
    },
    {
        "utterance": "Faranak Fattahi: Yeah, so when you start with primary tissue, it's not easy to capture the neurons because they're very diluted in the tissue. It's like less than 1% of the cells are neuronal or glia. So what we do from stem cells is we make them separately. So we make neurons, then we make intestinal epithelial cells or smooth muscle, and then we assemble them into co-cultures. So a lot of what we do initiates with just the one cell type, either just the neurons or just the epithelia. But then when we want to validate some of the key functions or pathways, that's where we really go with the more complex models because they are not as scalable. ",
        "annotations": {
            "explain or define term or concept": "Faranak explains the challenges of capturing neurons from primary tissue due to their low concentration and describes their approach of creating co-cultures from stem cells to address this issue.",
            "provide supporting evidence": "Faranak supports her explanation by stating that neurons and glia make up less than 1% of cells in primary tissue, justifying the use of stem cells.",
            "expand on existing idea": "Faranak elaborates on Robin's question about enteric organoids by detailing the process of creating co-cultures from stem cells, explaining why they start with single cell types and later move to complex models for validation."
        }
    },
    {
        "utterance": "Faranak Fattahi: And then with respect to what's there in the neuronal cultures, there are basically a number of different neurons intermixed. You have motor neurons, inhibitory and excitatory, you have the sensory component, you have a number of different interneurons, you have the glia. So it's really like a combination, a sample of what you might find in actual ENS tissue. So it's a good starting point for like something large scale where you want to get a sense of what could be responding to what metabolite or factors. But then you always have to follow that up with validations and tissue or the assemblies. ",
        "annotations": {
            "explain or define term or concept": "Faranak is explaining what is present in the neuronal cultures used in her research, including different types of neurons and glia, to clarify the composition for the team.",
            "provide supporting evidence": "Faranak supports her reasoning for using neuronal cultures as a starting point by stating they are a sample of actual ENS tissue and good for large-scale studies to understand responses to metabolites or factors, but follow-up with validation in more complex models is necessary."
        }
    },
    {
        "utterance": "Robin Michelle: Have you tried generating those organoids from different disease states? ",
        "annotations": {
            "ask clarifying question": "Robin Michelle asks Faranak to elaborate on whether she has generated organoids from different disease states, following up on Faranak's description of generating enteric organoids from stem cells and co-culturing them."
        }
    },
    {
        "utterance": "Faranak Fattahi: So the disease, yeah. So the diseases that we work on are motility disorders. So the first one we looked at was Hirschsprung disease, which is basically a developmental problem where parts of the GI don't have innervation. So, you know, it causes real severe obstruction in the colon. So we model those types of diseases, and now we're working on achalasia or gastroparesis, similarly lack of proper innervation or transmission. So, you know, motility is blocked. But, you know, thinking about these types of models in the context of microbial products, you know, you'd be basically taking normal cells with no genetic mutations and then exposing them to these metabolites or factors and looking at how they respond differentially. ",
        "annotations": {
            "explain or define term or concept": "Faranak explains Hirschsprung disease as a developmental problem where parts of the GI tract lack innervation, causing severe obstruction in the colon, and achalasia or gastroparesis as conditions with similar innervation or transmission problems leading to blocked motility.",
            "provide supporting evidence": "Faranak provides evidence of their work by stating they model motility disorders like Hirschsprung disease, achalasia, and gastroparesis, and are exploring how normal cells respond to microbial metabolites or factors in these disease models."
        }
    },
    {
        "utterance": "Faranak Fattahi: So we've done similar things in inflammation or in diabetes. We're looking at how fatty acids affect the glia, for instance, because of, you know, the correlation between diabetes and motility disorders. But we haven't really so far done anything with microbial products. So it'd be cool to test that out and see if you see any cell type of specific response and components of the ENS. ",
        "annotations": {
            "provide supporting evidence": "Faranak provides evidence of their work on inflammation and diabetes, and how fatty acids affect glia, relating it to the correlation between diabetes and motility disorders.",
            "present new idea": "Faranak suggests testing the effects of microbial products on cell type-specific responses and components of the ENS, which hasn't been done yet.",
            "explain or define term or concept": "Faranak explains their research on the effects of fatty acids on glia in the context of diabetes and motility disorders, clarifying the connection between these elements."
        }
    },
    {
        "utterance": "Robin Michelle: And the reason why I asked is because, you know, we collect biopsy samples all the time from people with, say, Parkinson's disease. And I didn't know if the degeneration would also be present in the enteric nervous system, which would make those sort of difficult to grow. Because, for example, we've tried growing colonic organoids from aged mice, like 24-month old mice, and they just don't grow because I think they're senescent, themselves just aren't as active anymore. So I was just, I guess, wondering about the how viable it is to try to harvest and grow these enteric organoids from. ",
        "annotations": {
            "provide_supporting_evidence": "Robin Michelle explains her reasoning for asking about generating organoids from different disease states by providing an example of their experience with aged mice.",
            "ask_clarifying_question": "Robin Michelle is asking for clarification on the viability of growing enteric organoids from diseased tissue, specifically in the context of Parkinson's disease and the potential for degeneration in the enteric nervous system."
        }
    },
    {
        "utterance": "Faranak Fattahi: Yeah. So the other issue with ICing them from primary tissue is their, the fully differentiated neurons don't survive the processing. So you enrich for progenitors and glia. So there's a little bit of a sampling error there too. And so when you're dealing with disease versus normal, would that sampling error be different in your disease versus wild type and would that interfere with your readout? So always a concern. But yeah, I mean, we can potentially, if you're starting from stem cells, you can put your Parkinson's mutation in your undifferentiated cells and then generate your neurons from that background and see if that mutation then affects the viability or the function of the neurons in any specific way. ",
        "annotations": {
            "explain or define term or concept": "Faranak explains the difficulty of capturing neurons from primary tissue due to their low concentration and the resulting enrichment for progenitors and glia, leading to sampling error.",
            "provide supporting evidence": "Faranak supports her explanation by pointing out the sampling error that arises from the enrichment process and how it might differ between diseased and normal samples, potentially affecting the readout.",
            "ask clarifying question": "Faranak poses a question about whether the sampling error would differ between diseased and wild-type samples and if it would impact the readout.",
            "present new idea": "Faranak suggests introducing Parkinson's mutation into undifferentiated stem cells to generate neurons and study the mutation's effect on neuronal viability and function."
        }
    }
]